The comparison between human leukocyte antigen system incidence in patients with bladder cancer and normal controls.
OBJECTIVE
To determine the frequency of human leukocyte antigen (HLA)-B5 in patients with bladder cancer compared with normal population.


METHODS
In this cross sectional study, from November 2009 until November 2010, 35 patients with pathologic diagnosis of bladder cancer who referred to urology clinic of Razi Hospital were studied. Also, 130 healthy transplant donation volunteers who referred for HLA-typing to Guilan Blood Transfusion Organization, were selected. Inclusion criterion was pathologic diagnosis of bladder cancer regardless of stage and grade of tumor. Exclusion criteria were presence of other urologic diseases. The information of these cases was extracted from medical records, collected and analyzed.


RESULTS
HLA-B5 was positive in 34.3% of the patient group and in 39.2% of the controls. Statistical analysis showed no significant association between HLA-B5 and bladder cancer (P = .15). There were no significant differences between grade (P = .107) and relapse (P = .327)of bladder tumor with presence of HLA-B5.


CONCLUSIONS
There was no significant association between HLA-B5 and bladder cancer. The grade and the relapse of tumor had no association with presence or absence of HLA-B5.
Urology and Nephrology Research Center, Guilan University of Medical Sciences, Rasht,Iran.
Siavash
S
Falahatkar
Urology Research Center, Guilan University of Medical Sciences. hadiseh_donyamali@yahoo.com.
Hadiseh
H
Donyamali
Urology and Nephrology Research Center, Guilan University of Medical Sciences, Rasht,Iran.
Mohammad Ali
MA
Joafshani
Urology and Nephrology Research Center, Guilan University of Medical Sciences, Rasht,Iran.
Reza
R
Shahrokhi Damavand
Urology and Nephrology Research Center, Guilan University of Medical Sciences, Rasht,Iran.
Saba
S
Hoda
Urology and Nephrology Research Center, Guilan University of Medical Sciences, Rasht,Iran.
Samaneh
S
Esmaeili
Urology and Nephrology Research Center, Guilan University of Medical Sciences, Rasht,Iran.
Keivan
K
Gholamjani Moghaddam
Urology and Nephrology Research Center, Guilan University of Medical Sciences, Rasht,Iran.
Sara
S
Nikpour
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000097:blood*; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D005260:Female; D015235:HLA-B Antigens / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000097:blood*; D009367:Neoplasm Staging; D001749:Urinary Bladder Neoplasms / Q000097:blood* / Q000473:pathology
D015235:HLA-B Antigens; C035270:HLA-B5 antigen